Imedex® is an industry leader in providing accredited, independent continuing medical education to health care professionals.
Accreditation
Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex®, LLC designates this live educational activity for a maximum 2.0 of AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Who Should Attend
This educational activity is specifically designed for gynecologic oncologists, medical oncologists, radiation oncologists, surgical oncologists, community oncologists, researchers, and healthcare professionals interested or involved in the care of patients with ovarian cancer and the consequences of this disease.
Objectives
After successful completion of this course, participants should be able to:
- Describe novel targeted agents advancing in clinical trials for ovarian cancer
- Apply personalized therapies based on specific tumor biology when available for patients with ovarian cancer
- Integrate emerging targeted therapies with conventional chemotherapy for ovarian cancer
- Prepare a personalized and evidence-based treatment plan for patients with advanced disease